Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Get Free Report) insider Brian Elsbernd sold 62,975 shares of the stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $22.98, for a total value of $1,447,165.50. Following the transaction, the insider now owns 188,564 shares of the company's stock, valued at approximately $4,333,200.72. This trade represents a 25.04 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.
Catalyst Pharmaceuticals Stock Up 1.3 %
CPRX stock traded up $0.29 during mid-day trading on Friday, reaching $21.96. The company had a trading volume of 1,021,369 shares, compared to its average volume of 1,261,681. The stock has a market capitalization of $2.67 billion, a P/E ratio of 18.61, a P/E/G ratio of 3.31 and a beta of 0.84. Catalyst Pharmaceuticals, Inc. has a one year low of $14.47 and a one year high of $24.64. The stock's 50-day simple moving average is $22.28 and its two-hundred day simple moving average is $21.51.
Institutional Investors Weigh In On Catalyst Pharmaceuticals
A number of hedge funds have recently added to or reduced their stakes in CPRX. Creative Planning raised its stake in shares of Catalyst Pharmaceuticals by 26.9% during the third quarter. Creative Planning now owns 12,724 shares of the biopharmaceutical company's stock valued at $253,000 after purchasing an additional 2,699 shares in the last quarter. Wealth Enhancement Advisory Services LLC raised its stake in shares of Catalyst Pharmaceuticals by 11.0% during the third quarter. Wealth Enhancement Advisory Services LLC now owns 20,017 shares of the biopharmaceutical company's stock valued at $398,000 after purchasing an additional 1,989 shares in the last quarter. Summit Global Investments raised its stake in shares of Catalyst Pharmaceuticals by 2.6% during the third quarter. Summit Global Investments now owns 77,292 shares of the biopharmaceutical company's stock valued at $1,537,000 after purchasing an additional 1,923 shares in the last quarter. CWA Asset Management Group LLC bought a new stake in shares of Catalyst Pharmaceuticals during the third quarter valued at about $534,000. Finally, Assetmark Inc. raised its position in Catalyst Pharmaceuticals by 2.4% in the third quarter. Assetmark Inc. now owns 72,245 shares of the biopharmaceutical company's stock worth $1,436,000 after acquiring an additional 1,704 shares in the last quarter. 79.22% of the stock is currently owned by institutional investors.
Analyst Upgrades and Downgrades
CPRX has been the subject of several research analyst reports. Baird R W upgraded Catalyst Pharmaceuticals to a "strong-buy" rating in a research note on Monday, February 3rd. Stephens reaffirmed an "overweight" rating and issued a $33.00 price objective on shares of Catalyst Pharmaceuticals in a report on Thursday, February 27th. Robert W. Baird lifted their price objective on shares of Catalyst Pharmaceuticals from $28.00 to $32.00 and gave the stock an "outperform" rating in a report on Monday, March 3rd. Truist Financial lifted their price objective on shares of Catalyst Pharmaceuticals from $30.00 to $36.00 and gave the stock a "buy" rating in a report on Monday, November 11th. Finally, Bank of America reaffirmed a "buy" rating and issued a $30.00 price objective on shares of Catalyst Pharmaceuticals in a report on Thursday, January 9th. Eight research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat, Catalyst Pharmaceuticals currently has an average rating of "Buy" and an average price target of $32.50.
View Our Latest Stock Analysis on Catalyst Pharmaceuticals
Catalyst Pharmaceuticals Company Profile
(
Get Free Report)
Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.
Read More
Before you consider Catalyst Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Catalyst Pharmaceuticals wasn't on the list.
While Catalyst Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
